TAS0728 is a potent and selective small molecule kinase inhibitor designed to target the Janus kinase 3 (JAK3) enzyme. By effectively blocking STAT3 activation, this compound is primarily utilized in preclinical… Read more
TAS0728 is a potent and selective small molecule kinase inhibitor designed to target the Janus kinase 3 (JAK3) enzyme. By effectively blocking STAT3 activation, this compound is primarily utilized in preclinical research settings to model autoimmune diseases and study complex cytokine-mediated signaling pathways. Laboratories working with this agent require high-quality reference standards and analytical tools to ensure accurate experimental outcomes. This category includes the parent drug alongside its deuterated analogue, TAS0728-d6, which serves as a stable isotope labelled internal standard. These compounds are essential for precise quantitative mass spectrometry analysis, facilitating rigorous impurity profiling and method validation. By incorporating these specialized materials into analytical workflows, researchers can achieve greater sensitivity and reproducibility when investigating the pharmacokinetics and downstream biological effects of this specific JAK3 inhibitor in diverse scientific studies.